Published in Blood Weekly, January 26th, 2006
"We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumors derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumors in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumor growth is reestablished," scientists reported in the journal Biochemical and Biophysical Research Communications.
"Similar findings were observed when the mice were treated with Gleevec (STI-571)," added X. Li and colleagues, Hospital for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.